[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-multifocal-leucoencephalopathy-pml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-multifocal-leucoencephalopathy-pml":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100592181","phase-2-t-cell-therapy-in-patients-with-pml-100592181",false,"NCT06990087","T-cell Therapy in Patients With PML","CurePML - Allogeneic HPyV-2-specific T-cell Therapy in Patients With Progressive Multifocal Leukoencephalopathy","Inclusion Criteria:\n\n* Adults\\* aged ≥ 18 years with PML (diagnosed ≤ 60 days before screening) associated with one or more of the following risk factors: lymphoproliferative diseases, immunosuppressive therapy, or lymphopenia\n* Signed written informed consent from subject and\u002For legal representative\n* HPyV-2 detection in CSF by PCR analysis or in brain biopsy\n\nExclusion Criteria:\n\n* PML caused by HIV\n* PML caused by natalizumab\n* PML occurring within five 5 years after hematopoietic stem-cell transplantation or CAR T cell therapy, or resulting from chronic lymphocytic leukemia (CLL)\n* Patients who are unable to follow the study protocol, either on their own or with the support of a reliable representative, will be excluded\n* Pregnancy or breastfeeding\n* Currently receiving chemotherapy\n* Present (within 2 weeks before screening visit) and continuous treatment with immune checkpoint inhibition therapy\n* Severe infections other than PML (e.g. sepsis, pneumonia)\n* Hypersensitivity to any of the components of the medications used\n* Inability to undergo MRI examination (e.g. implanted incompatible medical devices, claustrophobia)\n* Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)","ALL","18 Years",{"count":19,"type":20},23,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.",[26],"Progressive Multifocal Leucoencephalopathy (PML)","RECRUITING","2026-02-10",{"date":30,"type":31},"2026-02-12","ACTUAL",{"date":33,"type":31},"2026-02-06",{"date":35,"type":20},"2027-11",{"name":37,"class":38},"Hannover Medical School","OTHER",6]